ClinicalTrials.gg
Not yet recruitingNCT07881991Updated Oct 20, 2026

Phase 2 Study of SYH2066 Tablets Compared With Placebo in Chinese Adult Patients With Respiratory Syncytial Virus Infection.

A Phase 2 interventional study of SYH2066 and Placebo in Respiratory Syncytial Virus Infections, sponsored by CSPC Ouyi Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by CSPC Ouyi Pharmaceutical Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 2, Interventional, and Treatment

Updated Oct 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 30 studies in Respiratory Syncytial Virus Infections with a site in China — 8 open to participants now, 13 under way, 4 of them phase 3. Respiratory Syncytial Virus Infections · China.

Planned enrollment
16th of 25
80 · median 132
Started
2026
with 3 others
Phase 2
6 of 30
1 open now
Primary completion
2027-12
later than 11 of 12 live
Registered
30th of 30
by date
Lead sponsor
1 of 30
CSPC Ouyi Pharmaceutical Co., Ltd.

Among the 30 studies in Respiratory Syncytial Virus Infections with a site in China, this one is the 16th largest by planned enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2026, is one of 6 in phase 2, reaches primary completion later than 11 of the 12 other live ones, and was the 30th registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

8 of the 30 studies in Respiratory Syncytial Virus Infections with a site in China are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Respiratory Syncytial Virus Infections with a site in China, or all of them as a file.
02

Study summary

This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy, safety, and pharmacokinetic profile of SYH2066 tablets in adult patients with RSV infection. Approximately 80 adult patients with RSV infection are expected to be enrolled and assigned to three active treatment groups and one placebo group, with approximately 20 eligible participants per group. The study consists of a 3-day screening period, a 5-day treatment period, and an 8- to 10-day follow-up period. Throughout the study, safety assessments, PK blood sampling, nasopharyngeal (NP) swab collection, and RSV symptom recording will be performed

03

Conditions studied

  • Respiratory Syncytial Virus Infections
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all of the following criteria to be eligible for enrollment in this study:

  • 1. Aged 18 to 85 years (inclusive), male or female.
  • 2. (BMI) between 18 kg/m² and 35 kg/m² (inclusive).
  • 3. Presence of at least one of the following newly occurring respiratory tract infection symptoms or systemic symptoms (total symptom score ≥3 points); or worsening of pre-existing respiratory symptoms (total symptom score ≥3 points and an increase of at least 2 points from baseline):

    • Respiratory symptoms: cough, sore throat, nasal congestion, wheezing (whistling sound during breathing), cough with phlegm, and shortness of breath;
    • Systemic symptoms: headache, feeling feverish, body aches, fatigue, neck pain, sleep disturbance, and loss of appetite.
  • 4. Onset of RSV infection symptoms or worsening of pre-existing non-RSV infection symptoms meeting criterion 3 at enrollment, occurring within ≤72 hours prior to the first dose.
  • 5. Diagnosis of RSV infection confirmed by antigen or RT-PCR testing within 36 hours prior to the first dose.
  • 6. Participants and their partners agree to have no pregnancy plan and no sperm/egg donation plan from screening until 3 months after the last administration of the product, and voluntarily agree to use effective measures.
  • 7. Participants voluntarily participate in the study and sign the form (ICF).

Exclusion criteria

Exclusion Criteria:

Participants meeting any of the following criteria will be excluded from this study:

  • 1. Patients with definite diagnosis of pneumonia.
  • 2. Known concomitant acute respiratory infection other than RSV (e.g., influenza, COVID-19, mycoplasma) within 3 days prior to screening.
  • 3. Known severe gastrointestinal diseases affecting absorption of the study drug (e.g., severe persistent vomiting, malabsorption syndrome, short-bowel syndrome due to necrotizing enterocolitis, etc.).
  • 4. Any of the following cardiovascular or cerebrovascular events within 6 months prior to screening: unstable angina requiring hospitalization, myocardial infarction, coronary artery bypass grafting, percutaneous coronary intervention (diagnostic angiography and PCI performed >3 months ago are permitted), heart failure ( Class III or IV), atrial or ventricular arrhythmias requiring hospitalization (e.g., atrial fibrillation, ventricular tachycardia, etc.), pacemaker or defibrillator implantation, , or cerebrovascular event (e.g., stroke); or planned revascularization procedures (e.g., coronary artery bypass surgery) during the study.
  • 5. Awaiting or having received bone marrow transplantation, stem cell transplantation, or solid organ transplantation within 1 year prior to screening.
  • 6. History of current or previous (except for malignancies that are well controlled and do not affect the study progress or efficacy evaluation, such as completely resected basal cell carcinoma of the skin, carcinoma in situ of the cervix, or thyroid cancer).
  • 7. Severe or uncontrolled concomitant diseases, including but not limited to , cardiovascular, hematologic, respiratory, hepatobiliary, gastrointestinal, endocrine, urinary, psychiatric, or neurologic disorders, which, in the investigator's judgment, would increase the risk to the participant if enrolled.
  • 8. History of drug abuse, drug addiction, and/or alcohol abuse within 6 months prior to screening (alcohol abuse defined as weekly consumption of >14 units of alcohol: 1 unit = 360 mL beer, or 45 mL of 40% spirits, or 150 mL wine).
  • 9. Known allergy to the study drug or its components.
  • 10. Use of medications that may affect the efficacy or mechanism of the study drug within 5 half-lives prior to randomization (per the drug label; if half-life is unclear, within 7 days prior to randomization) or planned use during the study, including but not limited to: systemic antivirals (ribavirin, interferons, etc., excluding nucleos(t)ide analogues for and direct-acting antivirals for ), inhaled (except for and asthma patients on stable prior inhaled corticosteroid therapy), immunomodulators, and Chinese herbal medicines with antiviral activity, etc.
  • 11. Participation in another clinical trial within 3 months (or 5 half-lives, whichever is longer) prior to screening (except for those not receiving any intervention).
  • 12. At screening, clinical laboratory values meeting the following criteria: ≥3× or AST ≥3×ULN; serum ≥1.5×ULN.
  • 13. Positive -Ab test result.
  • 14. Positive pregnancy test or breastfeeding female patients.
  • 15. Patients who, after instruction by the investigator, are still unable to complete the Respiratory Infection Severity and Impact Questionnaire.
  • 16. Any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in the study.

Additional exclusion criteria for COPD participants:

  • 17. Acute exacerbation of COPD within 6 weeks prior to screening requiring treatment with systemic corticosteroids and/or antibiotics, or emergency room visit or hospitalization.
  • 18. More than 3 acute exacerbations of COPD in the past 12 months.
  • 19. Resting pulse oximetry (SpO₂) reading \<88% at screening, or long-term oxygen therapy (i.e., prescribed for ≥12 hours per day).
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    SYH2066 low dose

    Eligible participants will receive the protocol-specified dose orally for 5 days.

    Drug: SYH2066

  • Experimental
    SYH2066 medium dose

    Eligible participants will receive the protocol-specified dose orally for 5 days.

    Drug: SYH2066

  • Experimental
    SYH2066 high dose

    Eligible participants will receive the protocol-specified dose orally for 5 days.

    Drug: SYH2066

  • Placebo comparator
    Placebo

    Eligible participants will receive the protocol-specified dose orally for 5 days.

    Drug: Placebo

Interventions

  • DrugSYH2066

    Protocol-specified dose of SYH2066 tablets administered orally for 5 days.

  • DrugPlacebo

    Protocol-specified dose of placebo tablets administered orally for 5 days.

06

What researchers measure

Primary outcomes

  1. Area under the curve (AUC) of RSV RNA viral load measured by RT-qPCR in nasopharyngeal swab samples

    Nasopharyngeal swabs will be taken from Day 1 to Day 14 for RSV RNA quantification, and the area under the RSV RNA load-time curve will be derived from the measured values plotted against time.

    Time frame: Up to Day 14

Secondary outcomes

  1. Change from baseline in RSV RNA viral load at each visit (D2, D3, D4, D5, D6, D9, D14, ETV)during the study period

    Time frame: Up to Day 14

  2. Time from first dose to RSV RNA viral load falling below the lower limit of quantification (LLOQ)

    Time frame: Up to Day 14

  3. Percentage of participants with RSV RNA viral load below LLOQ from first dose

    Time frame: Up to Day 14

  4. Area under the curve (AUC) of the Respiratory Infection Severity and Impact Questionnaire score from Day 1 to Day 14

    Participants need complete the RIIQ questionnaire daily from Day 1 through Day 14, and the area under the time-based score curve will be estimated.

    Time frame: Up to Day 14

  5. Change from baseline in the Respiratony Infection Severity and lmpact Questionnaire score at each visit (02, D3,D4,D5, D6, D9, D14, ETV) after first dose

    Respiratory Infection Severity and Impact Questionnaire(RiiQ questionnaire) is mainly used to assess RSV symptoms in patients, including upper respiratory tract infection symptoms (sore throat and nasal congestion), symptoms of lower respiratory tract infection (cough, wheezing, sputum, shortness of breath), and system symptoms (fever, headache, neck pain, fatigue, lack of appetite, interrupted sleep, body aches). The questionnaire is divided into four grading categories of severity including none (0), mild (1), moderate (2) and severe (3).

    Time frame: Up to Day 14

  6. Time from first dose to resolution/recovery of all RSV symptoms

    Resolution/recovery of all RSV symptoms is defined as the concurrent fulfillment of all predefined symptom criteria as specified below, with the response sustained for ≥48 hours: * For symptoms not present before infection: reduction to a score of 0; * For symptoms present before infection: return to pre-infection level or better. RSV symptoms include following: 2 upper respiratory (stuffy nose, sore throat), 4 lower respiratory (cough, expectoration, wheezing, shortness of breath), and 7 systemic (feeling feverish, headache, body aches/pains, neck pain, trouble sleeping, tiredness, poor appetite).

    Time frame: Up to Day 14

  7. Time from first dose to relief of all RSV symptoms

    Relief of all RSV symptoms is defined as the concurrent fulfillment of all predefined symptom criteria as specified below, with the response sustained for ≥48 hours: * For symptoms not present before infection: reduction to a score of 0 or 1; * For symptoms present before infection and worsened by the current RSV infection: improvement of at least 1 point from baseline (pre-treatment); * For symptoms present before infection but not worsened by the current infection: maintained at pre-infection level or better. RSV symptoms include following: 2 upper respiratory (stuffy nose, sore throat), 4 lower respiratory (cough, expectoration, wheezing, shortness of breath), and 7 systemic (feeling feverish, headache, body aches/pains, neck pain, trouble sleeping, tiredness, poor appetite).

    Time frame: Up to Day 14

  8. Time-weighted average burden of RSV core symptoms (nasal congestion, body aches, sore throat, and cough with phlegm) over 0-96 h post-first dose

    It is defined as the AUC of the core symptom burden curve over 0-96 h divided by 96 h, where lower values indicate less overall symptom burden or faster improvement.

    Time frame: Up to Day 14

  9. Incidence and severity of adverse events (AEs)

    Any abnormalities in vital signs, physical examinations, laboratory tests, 12-lead electrocardiograms (ECGs), or other parameters observed in participants post-dose will be recorded as AEs.

    Time frame: Up to Day 14

  10. Time from first dose to resolution/recovery of RSV core symptoms (nasal congestion, body aches, sore throat, cough with phlegm)

    Resolution/recovery of RSV core symptoms is defined as the concurrent fulfillment of RSV core symptom criteria as specified below, with the response sustained for ≥24 hours: * For symptoms not present before infection: reduction to a score of 0; * For symptoms present before infection: return to pre-infection level or better.

    Time frame: Up to Day 14

  11. Time from first dose to resolution/recovery of respiratory symptoms

    Resolution/recovery of respiratory symptoms is defined as the concurrent fulfillment of respiratory symptoms criteria as specified below, with the response sustained for ≥24 hours: * For symptoms not present before infection: reduction to a score of 0; * For symptoms present before infection: return to pre-infection level or better. Respiratory symptoms include following:stuffy nose, sore throat, cough, expectoration, wheezing, shortness of breath.

    Time frame: Up to Day 14

  12. Time from first dose to resolution/recovery of lower respiratory tract symptoms

    Resolution/recovery of lower respiratory tract is defined as the concurrent fulfillment of lower respiratory tract symptom criteria as specified below, with the response sustained for ≥24 hours: * For symptoms not present before infection: reduction to a score of 0; * For symptoms present before infection: return to pre-infection level or better. Lower respiratory tract symptoms include following: cough, expectoration, wheezing, shortness of breath.

    Time frame: Up to Day 14

  13. Time from first dose to resolution/recovery of upper respiratory tract symptoms

    Resolution/recovery of upper respiratory tract is defined as the concurrent fulfillment of upper respiratory tract symptom criteria as specified below, with the response sustained for ≥24 hours: * For symptoms not present before infection: reduction to a score of 0; * For symptoms present before infection: return to pre-infection level or better. Upper respiratory tract symptoms include following: stuffy nose, sore throat.

    Time frame: Up to Day 14

  14. Time from first dose to resolution/recovery of systemic symptoms

    Resolution/recovery of systemic symptoms is defined as the concurrent fulfillment of systemic symptom criteria as specified below, with the response sustained for ≥24 hours: * For symptoms not present before infection: reduction to a score of 0; * For symptoms present before infection: return to pre-infection level or better. Systemic symptoms include following: feeling feverish, headache, body aches/pains, neck pain, trouble sleeping, tiredness, poor appetite.

    Time frame: Up to Day 14

  15. Time from first dose to relief of RSV core symptoms (nasal congestion, body aches, sore throat, cough with phlegm)

    Relief of RSV core symptoms is defined as the concurrent fulfillment of RSV core symptom criteria as specified below, with the response sustained for ≥24 hours: * For symptoms not present before infection: reduction to a score of 0 or 1; * For symptoms present before infection and worsened by the current RSV infection: improvement of at least 1 point from baseline (pre-treatment); * For symptoms present before infection but not worsened by the current infection: maintained at pre-infection level or better.

    Time frame: Up to Day 14

  16. Time from first dose to relief of respiratory symptoms

    Relief of respiratory symptoms is defined as the concurrent fulfillment of respiratory symptom criteria as specified below, with the response sustained for ≥24 hours: * For symptoms not present before infection: reduction to a score of 0 or 1; * For symptoms present before infection and worsened by the current RSV infection: improvement of at least 1 point from baseline (pre-treatment); * For symptoms present before infection but not worsened by the current infection: maintained at pre-infection level or better. Respiratory symptoms include following: stuffy nose, sore throat, cough, expectoration, wheezing, shortness of breath.

    Time frame: Up to Day 14

  17. Time from first dose to relief of lower respiratory tract symptoms

    Relief of lower respiratory tract symptoms is defined as the concurrent fulfillment of lower respiratory tract symptom criteria as specified below, with the response sustained for ≥24 hours: * For symptoms not present before infection: reduction to a score of 0 or 1; * For symptoms present before infection and worsened by the current RSV infection: improvement of at least 1 point from baseline (pre-treatment); * For symptoms present before infection but not worsened by the current infection: maintained at pre-infection level or better. Lower respiratory tract symptoms include following: cough, expectoration, wheezing, shortness of breath.

    Time frame: Up to Day 14

  18. Time from first dose to relief of upper respiratory tract symptoms

    Relief of upper respiratory tract symptoms is defined as the concurrent fulfillment of upper respiratory tract symptom criteria as specified below, with the response sustained for ≥24 hours: * For symptoms not present before infection: reduction to a score of 0 or 1; * For symptoms present before infection and worsened by the current RSV infection: improvement of at least 1 point from baseline (pre-treatment); * For symptoms present before infection but not worsened by the current infection: maintained at pre-infection level or better. Upper respiratory tract symptoms include following: stuffy nose, sore throat.

    Time frame: Up to Day 14

  19. Time from first dose to relief of systemic symptoms

    Relief of systemic symptoms is defined as the concurrent fulfillment of systemic symptom criteria as specified below, with the response sustained for ≥24 hours: * For symptoms not present before infection: reduction to a score of 0 or 1; * For symptoms present before infection and worsened by the current RSV infection: improvement of at least 1 point from baseline (pre-treatment); * For symptoms present before infection but not worsened by the current infection: maintained at pre-infection level or better. Systemic symptoms include following: feeling feverish, headache, body aches/pains, neck pain, trouble sleeping, tiredness, poor appetite.

    Time frame: Up to Day 14

  20. Change from baseline in MxA expression levels at each visit (D2, D3, D4, D5, D6, ETV) during the study

    Time frame: Up to Day 14

  21. Peak plasma concentration (Cmax)

    Time frame: Up to Day 14

  22. Time to maximum plasma concentration (Tmax)

    Time frame: Up to Day 14

  23. Terminal elimination half-life (t½)

    Time frame: Up to Day 14

  24. Apparent clearance (CL/F)

    Time frame: Up to Day 14

  25. Area under the plasma concentration-time curve

    Time frame: Up to Day 14

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Dec 2027, 13 months later.

Of 32 industry-sponsored phase 2 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's planned 13 months is above that.

Counting every sponsor, half of 37 studies reached it within 11 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2026
First posted
Oct 20, 2026
StartEst.
Nov 13, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Mar 31, 2028
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07881991
Responsible party
Sponsor
First posted
Oct 20, 2026
Start date
Nov 13, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Oct 20, 2026

Study contacts

Clinical Trials Information Group NA officer
Contact
ctr-contact@cspc.cn
86+0311-69085587

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion